Oral adenosine-5'-triphosphate disodium,
does it really help with Increased everyday energy and improvement of chronic fatigue independent of exercise?
research showsIdentified human trials are limited to repeated high-intensity performance and muscular fatigue in healthy exercisers or trained adults; no human intervention directly testing nonexercise everyday vitality or chronic-fatigue symptoms was identified, so the grade is ? and the score is null. Direct human trials identified by the search concern high-intensity performance in exercisers or trained adults. No human intervention was found for nonexercise everyday energy or the chronic-fatigue population-endpoint pair, so boundary rule ④ requires ? with a null score.
ads claimTransferring the biochemical fact that ATP is cellular energy currency and exercise-trial results into everyday energy charging or chronic-fatigue treatment is an unsupported extrapolation.
Useful facts when choosing a product
- PeakATP is an ATP-disodium ingredient studied for exercise performance; the existing exercise-performance verdict and this nonexercise everyday-energy/chronic-fatigue verdict address different efficacy axes.
- Exercise studies commonly used 400 mg/day, but this does not establish a treatment dose or efficacy for chronic fatigue.
- Short studies were generally tolerated, but gastrointestinal discomfort and limited long-term or patient-population safety data remain; persistent fatigue first warrants evaluation for anemia, thyroid disease, sleep disorders, infection, mental health conditions, and other causes.
What the research actually shows
Purpura 2017 assigned 42 healthy men to ATP disodium 400 mg/day or placebo for two weeks before repeated sprints and reported preserved late-bout peak power and muscular excitability. Wilson 2013 enrolled 24 resistance-trained men, with 21 completing a 12-week training study assessing strength, power, and lean mass. Both used exercise stress and performance endpoints; neither tested everyday vitality, idiopathic chronic fatigue, or fatigue scales and function in people with ME/CFS. The search identified no direct human intervention for the specified population-endpoint pair.
Why this is classified as ?
Direct human trials identified by the search concern high-intensity performance in exercisers or trained adults. No human intervention was found for nonexercise everyday energy or the chronic-fatigue population-endpoint pair, so boundary rule ④ requires ? with a null score.
Counterpoint. Exercise-context power and muscular-fatigue data can be evaluated on a separate efficacy axis. They do not substitute for evidence of nonexercise everyday vitality or chronic-fatigue symptom improvement.
Rejudgment record. New verdict — Direct human trials identified by the search concern high-intensity performance in exercisers or trained adults. No human intervention was found for nonexercise everyday energy or the chronic-fatigue population-endpoint pair, so boundary rule ④ requires ? with a null score.
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increase in everyday energy independent of exercise | ? | No directly evaluating human intervention was identified. |
| Improvement of chronic-fatigue symptoms | ? | No intervention of oral ATP itself was identified in chronic fatigue or ME/CFS patients. |
| Improved subjective vitality or reduced fatigue | ? | No result using a validated vitality or fatigue scale in a nonexercise context was identified. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Purpura M et al. 2017 | Randomized double-blind placebo-controlled trial | 2 | Supported by TSI USA | Repeated-sprint power, muscular excitability, and postexercise ATP | Preserved late-sprint power and excitability but did not assess nonexercise vitality or chronic fatigue. | Only indirect exercise-efficacy evidence |
| Wilson JM et al. 2013 | Randomized double-blind placebo- and diet-controlled training trial | 12 | Company-related authors and product support | Strength, power, lean mass, and training recovery | Assessed training adaptations, with no everyday-energy or chronic-fatigue patient endpoint. | Exercise-context only and small |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Oral adenosine-5'-triphosphate disodium (PeakATP; nucleotide supplement) × Increased everyday energy and improvement of chronic fatigue independent of exercise — Evidence Grade ?. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/oral-atp-daily-energy-chronic-fatigue/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.